Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q07890

UPID:
SOS2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q07890; B7ZKT6; D3DSB4; Q15503; Q17RN1

BACKGROUND:
The protein Son of sevenless homolog 2 (SOS2) serves as a key facilitator in the activation of the Ras protein, a critical player in cell growth and survival pathways. By catalyzing the replacement of GDP with GTP on Ras, SOS2 acts at the heart of one of the most fundamental signaling cascades in cellular biology.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Son of sevenless homolog 2 could open doors to potential therapeutic strategies for Noonan syndrome 9, a genetic disorder characterized by distinctive facial features, heart defects, and developmental issues. Targeting the molecular mechanisms involving SOS2 offers a promising approach to developing treatments for this syndrome and enhancing our understanding of Ras-mediated diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.